# Emerging novel methodologies to understand and strategically target long-lived plasma cells in vaccine design to induce durable immunity

## TL;DR

This paper reviews how long-lived plasma cells help create lasting immunity and how new methods can improve vaccine design to target these cells.

## Contribution

The paper introduces emerging technologies to better understand and target long-lived plasma cells for improved vaccine design.

## Key findings

- LLPCs are crucial for long-term immunity but their formation signals are not fully understood.
- New technologies can help study LLPC biology and improve vaccine strategies.
- Vaccine design decisions significantly impact immunological memory and LLPC generation.

## Abstract

Long-lived plasma cells (LLPCs) are a subset of antibody secreting cells (ASCs) that reside within lymphoid tissues, including the bone marrow (BM) and gut associated lymphoid tissues (GALT), and can secrete antigen-specific antibodies for up to decades or longer. Due to these traits, LLPCs serve as a crucial mediator for durable protective immunity. The signals needed to control the differentiation of LLPCs from naïve B cells, however, are not well understood. Accordingly, it remains a challenge to design vaccines that specifically drive LLPC generation and subsequent antibody durability. In this review, we discuss LLPC generation and heterogeneity following vaccination, vaccine design decisions known to impact immunological memory, and how novel emerging technologies can be used to inform on LLPC biology to enable LLPC targeting vaccine design.